AQST vs. ACIU, PBYI, ME, VSTM, IMMP, TSVT, ALDX, PYXS, XBIT, and XERS
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include AC Immune (ACIU), Puma Biotechnology (PBYI), 23andMe (ME), Verastem (VSTM), Immutep (IMMP), 2seventy bio (TSVT), Aldeyra Therapeutics (ALDX), Pyxis Oncology (PYXS), XBiotech (XBIT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical preparations" industry.
AC Immune (NASDAQ:ACIU) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
AC Immune has a net margin of 0.00% compared to AC Immune's net margin of -15.56%. AC Immune's return on equity of 0.00% beat Aquestive Therapeutics' return on equity.
AC Immune received 57 more outperform votes than Aquestive Therapeutics when rated by MarketBeat users. However, 66.44% of users gave Aquestive Therapeutics an outperform vote while only 62.16% of users gave AC Immune an outperform vote.
AC Immune has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.95, indicating that its share price is 195% more volatile than the S&P 500.
Aquestive Therapeutics has higher revenue and earnings than AC Immune. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aquestive Therapeutics had 13 more articles in the media than AC Immune. MarketBeat recorded 16 mentions for Aquestive Therapeutics and 3 mentions for AC Immune. Aquestive Therapeutics' average media sentiment score of 1.05 beat AC Immune's score of -0.31 indicating that AC Immune is being referred to more favorably in the media.
51.4% of AC Immune shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 8.4% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
AC Immune presently has a consensus target price of $16.00, indicating a potential upside of 580.85%. Aquestive Therapeutics has a consensus target price of $8.00, indicating a potential upside of 143.16%. Given Aquestive Therapeutics' higher possible upside, research analysts plainly believe AC Immune is more favorable than Aquestive Therapeutics.
Summary
Aquestive Therapeutics beats AC Immune on 10 of the 17 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
